JP2000264844A - Nutritive composition for kidney disease patient - Google Patents

Nutritive composition for kidney disease patient

Info

Publication number
JP2000264844A
JP2000264844A JP2000002493A JP2000002493A JP2000264844A JP 2000264844 A JP2000264844 A JP 2000264844A JP 2000002493 A JP2000002493 A JP 2000002493A JP 2000002493 A JP2000002493 A JP 2000002493A JP 2000264844 A JP2000264844 A JP 2000264844A
Authority
JP
Japan
Prior art keywords
composition
protein
group
renal
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000002493A
Other languages
Japanese (ja)
Inventor
Kozo Asaki
幸造 浅木
Ippei Yamaoka
一平 山岡
Masaru Kobayashi
勝 小林
Takuji Kamisako
卓司 上迫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP2000002493A priority Critical patent/JP2000264844A/en
Publication of JP2000264844A publication Critical patent/JP2000264844A/en
Pending legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To obtain the subject composition which improves the nutritive states of kidney disease patients and is useful for preventing arteriosclerosis and cardiovascular diseases caused by the arteriosclerosis by specifying the compounding ratio of three large nutriments (lipid, protein, carbohydrate). SOLUTION: This composition contains (A) lipids (for example, rice bran oil, fish oil), (B) proteins (for example, casein calcium, gelatin) and/or their hydrolyzates, and (C) carbohydrates (for example, dextrin) in amounts of 35-70%, 8-15% and <=57%, respectively, based on the total calorie of the composition. If necessary, the composition may furthermore be mixed with edible fibers (for example, cellulose), vitamins (for example, vitamin B6), minerals (for example, calcium), and an emulsifier (for example, xanthan gum). When all of the meal of a kidney disease patent is replaced by the above composition, the composition is usually preferably taken by the patient in an amount of about 25-40 kcal/day/kg of the body weight.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、急性もしくは慢性
の腎不全、腎炎等の腎疾患患者のための栄養組成物中の
三大栄養素の配合比率を規定した腎疾患患者用栄養組成
物、特に腎不全患者用栄養組成物に関する。
The present invention relates to a nutritional composition for a renal disease patient, in which the ratio of the three major nutrients in a nutritional composition for a renal disease patient such as acute or chronic renal insufficiency or nephritis is defined, in particular, The present invention relates to a nutritional composition for renal failure patients.

【0002】[0002]

【従来の技術】従来、腎疾患患者の食事療法としては、
腎臓への負担を軽減する目的で低蛋白食療法が有効とさ
れており、蛋白質の総エネルギーに占める割合を5〜8
%程度に抑えたものが殆どである。このような蛋白制限
の結果、腎疾患患者は栄養不良に陥り易く、また食事の
味等のコンプライアンスの面からも低蛋白食療法を長期
間継続することは困難であった。
2. Description of the Related Art Conventionally, dietary therapy for patients with renal disease includes:
A low protein diet is effective for reducing the burden on the kidney, and the ratio of protein to total energy is 5 to 8%.
Most of them are suppressed to about%. As a result of such protein restriction, renal disease patients are likely to suffer from malnutrition, and it has been difficult to maintain a low protein diet for a long period of time in terms of compliance with taste of meal and the like.

【0003】通常の腎不全食では蛋白質減少分のエネル
ギーを糖質で補うため、エネルギー補給の65〜70%
を糖質に依存している。そのため、通常の腎不全食で
は、総エネルギー量に占める糖質及び脂質の割合は糖質
65〜70%、脂質25〜30%であった。しかしなが
ら、エネルギー補給を糖質に依存した従来の腎不全食で
は、高トリグリセリド血症をさらに増長させることが危
惧されている。すなわち、腎不全患者においては、高ト
リグリセリド血症等の脂質代謝の異常が認められ、動脈
硬化症あるいはこれに起因する心血管系疾患を併発する
危険性が高かった。
[0003] In a normal renal failure diet, the energy for protein reduction is supplemented by carbohydrate, so that 65-70% of energy supplementation is required.
Depends on carbohydrates. Therefore, in a normal renal failure diet, the proportion of carbohydrate and lipid in the total energy was 65 to 70% of carbohydrate and 25 to 30% of lipid. However, there is a concern that a conventional renal failure diet that relies on carbohydrates for energy supplement may further increase hypertriglyceridemia. That is, in patients with renal insufficiency, abnormalities in lipid metabolism such as hypertriglyceridemia were observed, and there was a high risk that arteriosclerosis or a cardiovascular disease resulting therefrom would be complicated.

【0004】これに対して、腎不全患者に低糖質高脂肪
食を摂取させることにより、血中トリグリセリドの低下
等、血中脂質の改善がみられたとの報告がある(米田
ら、栄養学雑誌,Vol.43, No.1, 27-33, 1985)。しか
し、この報告では、従来の低蛋白質療法そのものについ
ては検討されておらず、従って低蛋白食療法による前記
した問題は解決されていない。
[0004] On the other hand, it has been reported that ingestion of a low-carbohydrate, high-fat diet in renal failure patients improved blood lipids such as a decrease in blood triglycerides (Yoneda et al., Nutrition Journal) , Vol.43, No.1, 27-33, 1985). However, this report does not examine the conventional low protein therapy itself, and thus does not solve the above-mentioned problems caused by the low protein diet.

【0005】[0005]

【発明が解決しようとする課題】本発明は、腎不全等の
腎疾患患者の栄養状態を改善し、かつ動脈硬化とこれに
起因する心血管系疾患を予防するのに最適な腎疾患患者
用栄養組成物を提供することを目的とする。
DISCLOSURE OF THE INVENTION The present invention relates to a method for improving the nutritional status of patients with renal diseases such as renal failure and for preventing atherosclerosis and cardiovascular diseases resulting therefrom, which are optimal for patients with renal diseases. It is intended to provide a nutritional composition.

【0006】[0006]

【課題を解決するための手段】本発明者らは、腎疾患患
者における栄養状態および腎機能の改善を目的に三大栄
養素(蛋白質、糖質、脂質)の至適配合比率について鋭
意研究を重ねた結果、蛋白質量を高めても、総熱量に占
める脂質の割合を高くし、糖質の割合を低くすることに
より、高トリグリセリド血症を増長させることがなく、
それゆえ従来の腎疾患患者への治療食としては不可能と
されてきた健常者と同等の蛋白質量を投与することがで
きるという新たな知見を見出し、本発明を完成するに至
った。
Means for Solving the Problems The present inventors have conducted intensive studies on the optimal mixing ratios of the three major nutrients (proteins, carbohydrates and lipids) for the purpose of improving nutritional status and renal function in patients with renal disease. As a result, even if the protein mass is increased, the proportion of lipids in the total caloric value is increased, and the proportion of carbohydrates is reduced, without increasing hypertriglyceridemia,
Therefore, the present inventors have found a new finding that it is possible to administer a protein equivalent to a healthy person, which has been considered impossible as a therapeutic diet for conventional renal disease patients, and have completed the present invention.

【0007】すなわち、本発明の腎疾患患者用栄養組成
物、総熱量に占める脂質の割合が35〜70%、蛋白質
及び/又はその分解物の割合が8〜15%であり、且つ
糖質の割合が57%以下であることを特徴とするもので
ある。この腎疾患患者用栄養組成物は、特に腎不全患者
用栄養組成物として好適である。
That is, the nutritional composition for a patient with renal disease of the present invention, wherein the ratio of lipid to total calorie is 35 to 70%, the ratio of protein and / or its degradation product is 8 to 15%, and The ratio is not more than 57%. This nutritional composition for patients with renal disease is particularly suitable as a nutritional composition for patients with renal failure.

【0008】[0008]

【発明の実施の形態】本発明の栄養組成物は、前記のよ
うに総熱量に占める脂質の割合を35〜70%とし、糖
質の割合を57%以下とし、蛋白質の割合を8〜15%
とするものである。なお、上記糖質の総熱量に占める割
合は少ないほど好ましいが、通常、少なくとも10%程
度であればよい。
BEST MODE FOR CARRYING OUT THE INVENTION As described above, the nutritional composition of the present invention has a fat content of 35 to 70%, a carbohydrate content of 57% or less, and a protein content of 8 to 15% of the total calorific value. %
It is assumed that. The ratio of the above-mentioned saccharides to the total calorific value is preferably as small as possible, but it is usually sufficient if the ratio is at least about 10%.

【0009】総熱量に占める脂質の割合が前記範囲を下
回る場合、これに伴って糖質の割合が増えるため、血中
脂質量が増大し、高トリグリセリド血症等の脂質代謝の
異常を増長させるおそれがある。一方、総熱量に占める
脂質の割合が前記範囲を超える場合、血中トリグリセリ
ドの増大はみられないが、コレステロールが増大して高
コレステロール血症となり、腎障害の悪化につながるお
それがある。また、総熱量に占める糖質の割合が前記範
囲を超える場合、高トリグリセリド血症等の脂質代謝の
異常を増長させるおそれがある。
[0009] When the proportion of lipids in the total calories is below the above range, the proportion of carbohydrates is increased accordingly, so that the amount of lipids in the blood is increased and abnormalities in lipid metabolism such as hypertriglyceridemia are increased. There is a risk. On the other hand, when the proportion of lipids in the total calories exceeds the above range, no increase in blood triglyceride is observed, but cholesterol increases to cause hypercholesterolemia, which may lead to deterioration of renal disorder. In addition, when the proportion of the carbohydrate in the total calorie exceeds the above range, abnormalities in lipid metabolism such as hypertriglyceridemia may be increased.

【0010】さらに、総熱量に占める蛋白質の割合が前
記範囲を下回る場合には、患者の栄養状態を改善できな
くなる。一方、総熱量に占める蛋白質の割合が前記範囲
を超える場合には、腎臓への負担が大きくなり、腎障害
の悪化をひき起こすおそれがあるので、好ましくない。
具体的には、蛋白質35〜80重量部に対し、糖質30
0重量部以下、脂質65〜165重量部とするのがよ
い。
[0010] Further, when the ratio of the protein to the total caloric value is lower than the above range, the nutritional status of the patient cannot be improved. On the other hand, if the proportion of the protein in the total calorific value exceeds the above range, the burden on the kidney is increased, which may cause deterioration of the renal disorder, which is not preferable.
Specifically, carbohydrate 30 to 35 to 80 parts by weight of protein
The content is preferably 0 parts by weight or less, and 65 to 165 parts by weight of lipid.

【0011】上記蛋白質としては、例えばカゼインカル
シウム等のカゼイン塩、鶏卵蛋白質、乳蛋白質、肉蛋白
質等の動物性蛋白質;大豆蛋白質等の植物性蛋白質;ゼ
ラチン等が挙げられる。また、蛋白質の分解物(大豆ペ
プチド等)やアミノ酸を、上記の蛋白質と共に、または
蛋白質に代えて使用してもよい。蛋白質またはその分解
物は1種のみを用いてもよく、2種以上を組合わせて用
いてもよい。
Examples of the above proteins include casein salts such as calcium caseinate, animal proteins such as chicken egg protein, milk protein and meat protein; vegetable proteins such as soybean protein; and gelatin. In addition, protein degradation products (such as soybean peptides) and amino acids may be used together with or in place of the above-mentioned proteins. One type of protein or its degradation product may be used alone, or two or more types may be used in combination.

【0012】脂質としては、例えば米糠油、大豆油、綿
実油、サフラワー油、コーン油、菜種油、パーム油、シ
ソ油、エゴマ油、ヤシ油等の植物油;牛油等の動物油;
魚油;合成トリグリセリド等が挙げられ、これらは1種
のみを用いてもよく2種以上を組合わせて用いてもよ
い。好ましくは、脂質中の多価不飽和脂肪酸含量が高く
なるような脂質を用いる。
Examples of lipids include vegetable oils such as rice bran oil, soybean oil, cottonseed oil, safflower oil, corn oil, rapeseed oil, palm oil, perilla oil, perilla oil, coconut oil and the like; animal oils such as cow oil;
Fish oil; synthetic triglyceride, etc., and these may be used alone or in combination of two or more. Preferably, a lipid having a high polyunsaturated fatty acid content in the lipid is used.

【0013】糖質としては、例えばマルトデキストリ
ン、デキストリン、粉飴、さらにブドウ糖、果糖等の単
糖類、マルトース、乳糖等の二糖類、グラニュー糖等が
挙げられる。糖質は1種のみを用いてもよく、2種以上
を組合わせて用いてもよい。好ましくは、マルトデキス
トリン、デキストリン等の多糖類を用いるのがよい。本
発明では、上記各成分以外に従来より種々の栄養組成物
に添加されている食物繊維、ビタミン類、ミネラル類、
乳化剤等を必要に応じて添加することができる。食物繊
維、ビタミン類およびミネラル類は、腎不全等の腎疾患
の病態を考慮した組成とするのが好ましい。
Examples of the saccharide include maltodextrin, dextrin, candy starch, monosaccharides such as glucose and fructose, disaccharides such as maltose and lactose, and granulated sugar. One type of saccharide may be used alone, or two or more types may be used in combination. Preferably, polysaccharides such as maltodextrin and dextrin are used. In the present invention, dietary fiber, vitamins, minerals that have been conventionally added to various nutritional compositions other than the above components,
An emulsifier and the like can be added as needed. It is preferable that the dietary fiber, vitamins and minerals have a composition taking into account the pathology of renal diseases such as renal failure.

【0014】食物繊維としては、例えばセルロース、リ
グニン、レジスタントスターチ、ポリデキストロース、
オリゴ糖等の難消化性の多糖類が挙げられる。
Examples of the dietary fiber include cellulose, lignin, resistant starch, polydextrose,
Examples include indigestible polysaccharides such as oligosaccharides.

【0015】ビタミン類としては、例えばビタミンA、
ビタミンB1 、ビタミンB6 、ビタミンB12、ビタミン
C、ビタミンD、ビタミンE、ナイアシン、葉酸、パン
トテン酸等の脂溶性または水溶性のビタミン類が挙げら
れ、これらは1種のみを用いてもよく、2種以上を組合
わせて用いてもよい。ただし、腎疾患患者が対象である
ため、ビタミンB6 や葉酸は健常人の必要量以上配合す
るのがよく、ビタミンAやビタミンDは健常人の必要量
以下とするのが好ましい。
As vitamins, for example, vitamin A,
Fat-soluble or water-soluble vitamins such as vitamin B 1 , vitamin B 6 , vitamin B 12 , vitamin C, vitamin D, vitamin E, niacin, folic acid, pantothenic acid, and the like. Also, two or more kinds may be used in combination. However, since it is intended for patients with renal disease, it is preferable that vitamin B 6 and folic acid be mixed in more than the required amount for healthy individuals, and that vitamin A and vitamin D be less than the required amounts for healthy individuals.

【0016】ミネラル類としては、例えばカルシウム、
鉄、ナトリウム、カリウム、リン、マグネシウム等が挙
げられ、これらは1種のみを用いてもよく、2種以上を
組合わせて用いてもよい。ただし、腎疾患患者が対象で
あるため、ナトリウム、カリウム、リン等の配合量は健
常人の必要量以下とするのが好ましい。
As minerals, for example, calcium,
Examples thereof include iron, sodium, potassium, phosphorus, and magnesium, and these may be used alone or in combination of two or more. However, since the target is a patient with renal disease, the amount of sodium, potassium, phosphorus and the like is preferably not more than that required for a healthy person.

【0017】乳化剤としては、例えばグリセリン脂肪酸
エステル、ショ糖脂肪酸エステル、ソルビタン脂肪酸エ
ステル、プロピレングリコール脂肪酸エステル、リン脂
質、アラビアガム、トラガントガム、キサンタンガム、
グアガム、ローカストビーンガム等が挙げられる。
Examples of the emulsifier include glycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, propylene glycol fatty acid ester, phospholipid, gum arabic, tragacanth gum, xanthan gum,
Guar gum, locust bean gum and the like.

【0018】また、上記した成分以外にも、例えばクエ
ン酸、果汁等の呈味成分、コーヒー風味、抹茶風味、ミ
ルク風味等のフレーバー等を適宜配合することができ
る。
In addition to the above components, flavor components such as citric acid and fruit juice, and flavors such as coffee flavor, matcha flavor and milk flavor can be appropriately blended.

【0019】本発明の栄養組成物は、上記した各成分を
混合し乾燥した粉末状、固形状、ペースト状、流動食等
の種々の医薬品や食品の形態で使用することができ、こ
れらは直接摂取してもよく、あるいは摂取時に水または
湯に溶解ないし分散させて摂取することもできる。ま
た、本発明の栄養組成物は、腎疾患患者の1日の食事の
全てまたはその一部と置き換えて摂取することもでき
る。
The nutritional composition of the present invention can be used in the form of various pharmaceuticals and foods, such as powders, solids, pastes, liquid foods, etc., which are obtained by mixing and drying the above-mentioned components. They may be taken or dissolved or dispersed in water or hot water when taken. In addition, the nutritional composition of the present invention can be taken in place of all or part of a daily meal of a patient with renal disease.

【0020】流動食の場合、その調製は常法に従って行
うことができる。すなわち、各成分を秤量し、水に投入
して充分に混合した後、乳化させ、レトルト・パウチ内
に充填密封し、殺菌処理を行うことによって流動食を製
造することができる。しかし、腎疾患患者が対象である
ため水分量は抑えた方がよく、熱量は流動食全体で10
0ml当たり100〜300kcal、好ましくは20
0kcal以上となるようにそれぞれの配合量を調整す
る。
In the case of a liquid food, its preparation can be carried out according to a conventional method. That is, a liquid food can be produced by weighing each component, putting it in water, mixing well, emulsifying, filling and sealing in a retort pouch, and performing a sterilization treatment. However, since it is intended for patients with renal disease, it is better to keep the water content low, and the calorie is 10
100-300 kcal per 0 ml, preferably 20
The respective amounts are adjusted so as to be 0 kcal or more.

【0021】本発明の栄養組成物の摂取量は、食事を全
て本発明の栄養組成物に置き換える場合には、通常、腎
疾患患者に対して体重1kgあたり約25〜40kca
l/日とするのが適当である。このようにして得られる
本発明の栄養組成物は、従来の腎疾患患者への栄養補給
とは異なり、腎機能を悪化させることなく栄養状態の改
善が可能となることはもとより、血中トリグリセリドの
減少といった脂質代謝の改善による腎疾患の進展予防や
動脈硬化症とこれに起因する心血管系疾患の予防も可能
となる。
When the whole diet is replaced with the nutritional composition of the present invention, the intake of the nutritional composition of the present invention is usually about 25 to 40 kca / kg body weight for patients with renal disease.
1 / day is appropriate. The nutritional composition of the present invention obtained in this way is different from conventional nutritional supplementation for patients with renal disease, in addition to being able to improve the nutritional state without deteriorating renal function, as well as blood triglyceride. Improvement of lipid metabolism such as reduction can prevent the development of renal disease and prevent arteriosclerosis and cardiovascular disease caused by it.

【0022】以下、実施例を挙げて本発明の栄養組成物
を説明するが、本発明は以下の実施例のみに限定される
ものではない。
Hereinafter, the nutritional composition of the present invention will be described with reference to examples, but the present invention is not limited to only the following examples.

【実施例】表1〜表3に示す各栄養組成物を調製した。EXAMPLES Nutrient compositions shown in Tables 1 to 3 were prepared.

【0023】[0023]

【表1】 [Table 1]

【0024】[0024]

【表2】 [Table 2]

【0025】[0025]

【表3】 [Table 3]

【0026】表1および表2に示す栄養組成物(試験
食)は、それぞれ同表に示す配合量で各成分を混合して
調製した通常の蛋白食群であって、Pro12は蛋白質
カロリー比が12%、Pro9は蛋白質カロリー比が9
%であることを示している。そして、各試料番号に付し
たL,MおよびHの順で脂質カロリー比が高く糖質カロ
リー比が低くなる。ここで、Pro12/M、Pro1
2/H、Pro9/MおよびPro9/Hは本発明にか
かる組成を有するものであるので、それぞれ製造例1〜
4とした。
The nutritional compositions (test meals) shown in Tables 1 and 2 are ordinary protein food groups prepared by mixing the respective components in the amounts shown in the same table, and Pro12 has a protein calorie ratio. 12%, Pro9 has a protein calorie ratio of 9
%. Then, the lipid calorie ratio increases in the order of L, M, and H assigned to each sample number, and the saccharide calorie ratio decreases. Here, Pro12 / M, Pro1
Since 2 / H, Pro9 / M and Pro9 / H have the composition according to the present invention, Production Examples 1 to 9, respectively.
And 4.

【0027】一方、表3に示す栄養組成物(試験食)
は、それぞれ同表に示す配合量で各成分を混合して調製
した低蛋白食群(蛋白質カロリー比:6%)であって、
試料番号Pro6/L、Pro6/MおよびPro6/
Hの順で脂質カロリー比が高く糖質カロリー比が低くな
る。ここで、Pro6/Lは蛋白質、糖質および脂質の
カロリー比が通常の腎不全食と同じである。
On the other hand, the nutritional composition (test food) shown in Table 3
Is a low protein diet group (protein calorie ratio: 6%) prepared by mixing each component in the amount shown in the same table,
Sample numbers Pro6 / L, Pro6 / M and Pro6 /
In the order of H, the lipid calorie ratio increases and the saccharide calorie ratio decreases. Here, Pro6 / L has the same caloric ratio of proteins, carbohydrates and lipids as a normal renal failure diet.

【0028】なお、表1〜表3で、ミネラル類およびビ
タミン類は、AIN−76処方の混合物をいう。
In Tables 1 to 3, minerals and vitamins refer to mixtures having an AIN-76 formulation.

【0029】次に、腎不全モデル動物を用いた試験例を
示す。 試験例1 4週令のウイスター系雄性ラットを用い、ネンブタール
麻酔下に左腎臓の75%を切除し、更にその2週間後、
右腎臓を全摘出して腎不全ラットを60匹作製した。右
腎臓全摘出から2週間後に、血漿クレアチニン濃度が
0.9〜1.7mg/dlの範囲にあるラット48匹を
腎不全ラットの中から選定し、市販固形飼料(CRF
1;オリエンタル酵母工業社製)にて1週間予備飼育し
た後、8匹ずつ6群に群分けし、各群に表1および表3
に示す組成の試験食を15週間自由摂取させた。また、
正常ラットに市販固形飼料を与える無処置群を設けた。
Next, a test example using a renal failure model animal will be described. Test Example 1 Using a 4-week-old male Wistar rat, 75% of the left kidney was excised under Nembutal anesthesia, and two weeks later,
The right kidney was completely removed and 60 rats with renal failure were produced. Two weeks after the total nephrectomy of the right kidney, 48 rats having a plasma creatinine concentration in the range of 0.9 to 1.7 mg / dl were selected from rats with renal insufficiency, and commercially available solid feed (CRF)
1; Oriental Yeast Co., Ltd.) for one week, and then divided into 6 groups of 8 animals each.
Was freely taken for 15 weeks. Also,
An untreated group was provided in which normal rats were fed a commercial chow.

【0030】試験食摂取開始前(0)、3、6、9、1
2、15週目に、それぞれ動物を個別代謝ケージに入れ
2日間自由摂餌させた。さらに12時間の絶食の後、エ
ーテル麻酔下に眼底採血と体重測定を行った。得られた
血液サンプルは遠心分離(3000rpm、10分、4
℃)し、血漿を用いてトリグリセリド(TG)およびク
レアチニン(Cre)を測定した。測定は血液生化学分
析装置(フジメディカル(株)製の「フジドライケム5
500」)を用いて行った。
Before ingestion of test food (0), 3, 6, 9, 1
At weeks 2 and 15, animals were placed in individual metabolic cages and allowed free access for 2 days. After an additional 12 hours of fasting, fundus blood sampling and body weight measurement were performed under ether anesthesia. The obtained blood sample was centrifuged (3000 rpm, 10 minutes, 4 minutes).
C), and plasma was used to measure triglyceride (TG) and creatinine (Cre). The measurement was performed using a blood biochemical analyzer (Fuji Dry Chem 5 manufactured by Fuji Medical Co., Ltd.).
500 ").

【0031】測定結果は平均値±標準偏差にて示し、統
計処理は、各試験食群間でTukey 法を用いて行った。統
計結果は、従来の腎不全食であるPro6/L群あるい
はPro12/L群と各試験食群の間の有意差(p<
0.05)で示した。腎疾患の指標である血漿クレアチ
ニン量の測定結果を表4に示す。
The measurement results are shown as an average value ± standard deviation, and statistical processing was performed between each test meal group using the Tukey method. The statistical results show a significant difference (p <) between the Pro6 / L group or Pro12 / L group, which is a conventional renal failure diet, and each test diet group.
0.05). Table 4 shows the measurement results of the amount of plasma creatinine, which is an indicator of kidney disease.

【0032】[0032]

【表4】 [Table 4]

【0033】表4から明らかなように、従来の腎不全食
群(Pro6/L)と同等の脂質カロリー比で蛋白質カ
ロリー比を高めたPro12/L群では、9週目以降よ
りPro6/L群との間に有意差が認められるようにな
り、腎機能が悪化する傾向を示した。これに対して、本
発明にかかる製造例1群(Pro12/M)および製造
例2群(Pro12/H)では、従来の腎不全食群(P
ro6/L)と比較して有意差がなく、蛋白質カロリー
比を高めたにもかかわらず、腎機能の悪化傾向は認めら
れなかった。次に、血中脂質量を示す血漿トリグリセリ
ド量の測定結果を表5に示す。
As is clear from Table 4, in the Pro12 / L group in which the protein caloric ratio was increased at the same lipid caloric ratio as that of the conventional renal failure diet group (Pro6 / L), the Pro6 / L group started from week 9 onward. And a significant difference was observed between them, indicating a tendency for renal function to deteriorate. In contrast, in Production Example 1 Group (Pro12 / M) and Production Example 2 Group (Pro12 / H) according to the present invention, the conventional renal failure diet group (P12 / M)
ro6 / L), there was no significant difference, and despite the increased protein calorie ratio, no tendency for deterioration of renal function was observed. Next, Table 5 shows the measurement results of the plasma triglyceride level, which indicates the blood lipid level.

【0034】[0034]

【表5】 [Table 5]

【0035】表5から明らかなように、低蛋白食群(P
ro6群)および通常の蛋白食群(Pro12群)はい
ずれも脂質カロリー比を上げることにより血中トリグリ
セリド量が低下する傾向がみられた。以上のことから、
蛋白質カロリー比を通常食並に高めたPro12群で
は、脂質カロリー比を高めることにより、血中トリグリ
セリド量を増大させず、かつ腎障害の悪化をも抑制でき
ることがわかる。
As is clear from Table 5, the low protein diet group (P
Both the ro6 group and the normal protein diet group (Pro12 group) tended to decrease the blood triglyceride level by increasing the lipid calorie ratio. From the above,
In the Pro12 group in which the protein calorie ratio was increased to the same level as a normal diet, it can be seen that increasing the lipid calorie ratio does not increase the amount of triglyceride in blood and can also suppress the deterioration of renal impairment.

【0036】また、体重の増加率(平均値)を図1に示
す。図1から明らかなように、蛋白質カロリー比の低い
Pro6群ではいずれも体重増加の抑制がみられたが、
蛋白質カロリー比の高いPro12群では体重が順調に
増加した。このことから、Pro12群では栄養状態が
改善されていることがわかる。
FIG. 1 shows the rate of increase in body weight (average value). As is evident from FIG. 1, in the Pro6 group having a low protein calorie ratio, suppression of weight gain was observed in all cases,
Body weight increased steadily in the Pro12 group with a high protein calorie ratio. This indicates that the nutritional status is improved in the Pro12 group.

【0037】試験例2 4週令のウイスター系雄性ラットを用い、ネンブタール
麻酔下に左腎臓の75%を切除し、更にその2週間後、
右腎臓を全摘出して腎不全ラットを60匹作製した。右
腎臓全摘出から2週間後に、血漿クレアチニン濃度が
1.1〜1.9mg/dlの範囲にあるラット40匹を
腎不全ラットの中から選定し、市販固形飼料(CRF
1;オリエンタル酵母工業社製)にて1週間予備飼育し
た後、10匹ずつ4群に群分けし、各群に表2および表
3に示す組成の試験食を6週間自由摂取させた。また、
正常ラットに市販固形飼料を与える無処置群を設けた。
Test Example 2 Using 4-week-old male Wistar rats, 75% of the left kidney was excised under Nembutal anesthesia, and two weeks later,
The right kidney was completely removed and 60 rats with renal failure were produced. Two weeks after the total nephrectomy of the right kidney, 40 rats whose plasma creatinine concentration was in the range of 1.1 to 1.9 mg / dl were selected from rats with renal insufficiency, and commercially available solid feed (CRF)
1; Oriental Yeast Co., Ltd.) for 1 week, and the animals were divided into 4 groups of 10 animals, and each group was allowed to freely ingest a test meal having the composition shown in Tables 2 and 3 for 6 weeks. Also,
An untreated group was provided in which normal rats were fed a commercial chow.

【0038】試験食摂取開始前(0)、3、6週目に、
それぞれ動物を個別代謝ケージに入れ2日間自由摂餌さ
せた。さらに12時間の絶食の後、エーテル麻酔下に眼
底採血を行った。得られた血液サンプルは遠心分離(3
000rpm、10分、4℃)し、血漿を用いて尿素窒
素(UN)を測定した。測定は血液生化学分析装置(フ
ジメディカル(株)製の「フジドライケム5500」)
を用いて行った。
Before the start of the test food intake (0), 3 and 6 weeks,
Each animal was placed in a separate metabolic cage and allowed free access for 2 days. After an additional 12 hours of fasting, blood was collected from the fundus under ether anesthesia. The obtained blood sample was centrifuged (3
000 rpm, 10 minutes, 4 ° C.), and urea nitrogen (UN) was measured using plasma. The measurement was performed using a blood biochemical analyzer (“Fuji Dry Chem 5500” manufactured by Fuji Medical Co., Ltd.).
This was performed using

【0039】測定結果は平均値±標準偏差にて示し、統
計処理は、各試験食群間でTukey 法を用いて行った。統
計結果は、従来の腎不全食であるPro6/L群あるい
はPro9/L群と各試験食群の間の有意差(p<0.
05)で示した。腎疾患の指標である血漿尿素窒素量の
変動率を表6に示す。
The measurement results are shown as an average value ± standard deviation, and statistical processing was performed between each test meal group using the Tukey method. Statistical results indicate a significant difference (p <0.p.) Between the conventional diet group of renal failure Pro6 / L group or Pro9 / L group and each test diet group.
05). Table 6 shows the fluctuation rate of the plasma urea nitrogen level, which is an index of renal disease.

【0040】[0040]

【表6】 [Table 6]

【0041】表6から明らかなように、従来の腎不全食
群(Pro6/L群)と同等の脂質カロリー比で蛋白質
カロリー比を高めたPro9/L群では、Pro6/L
群と比べて、尿素窒素の増加率が高い傾向を示した。こ
れに対して、本発明にかかるPro9/M(製造例3)
群およびPro9/H(製造例4)群では、Pro9/
L群に比べて尿素窒素の上昇率が明らかに抑制され、従
来の腎不全食群(Pro6/L群)よりも尿素窒素の上
昇率が抑制されていた。以上のことから、蛋白質カロリ
ー比を通常の腎不全食より高めたPro9群では、脂質
カロリー比を高めることにより、血漿尿素窒素量の増大
を抑制し、腎臓への負担軽減効果があることがわかっ
た。
As is clear from Table 6, in the Pro9 / L group in which the protein calorie ratio was increased at the same lipid calorie ratio as the conventional renal failure diet group (Pro6 / L group), Pro6 / L
The increase rate of urea nitrogen tended to be higher than that of the group. On the other hand, Pro9 / M according to the present invention (Production Example 3)
In the group and Pro9 / H (Preparation Example 4) group, Pro9 / H
The increase rate of urea nitrogen was clearly suppressed as compared with the L group, and the increase rate of urea nitrogen was suppressed as compared with the conventional renal failure diet group (Pro6 / L group). From the above, it was found that in the Pro9 group in which the protein calorie ratio was higher than that in the normal renal failure diet, increasing the lipid calorie ratio suppressed the increase in the amount of plasma urea nitrogen and had an effect of reducing the burden on the kidney. Was.

【0042】実施例1 下記処方に従って、各成分を秤量した。 (成分) (原料) (配合量) (熱量) 蛋白質 カゼインCa 50.0g 200kcal 脂質 大豆油 105.0g 945kcal 糖質 デキストリン 195.0g 780kcal ビタミン類 ビタミンA 1111IU ビタミンB1 778μg ビタミンB2 1000μg ビタミンB6 5.0mg ビタミンB12 4.4μg ビタミンC 111mg ビタミンD 100IU ビタミンE 17.8mg ナイアシン 13.3mg 葉酸 400μg パントテン酸 7.8mg ミネラル ナトリウム 150mg カルシウム 667mg カリウム 300mg リン 200mg マグネシウム 100mg 鉄 11.1mg 亜鉛 16.7mg 乳化剤 グリセリン脂肪酸 エステル 2g 食物繊維 オリゴ糖 0.44g 香料 ミルク風味 0.90mLExample 1 Each component was weighed according to the following recipe. (Ingredients) (Raw materials) (Blending amount) (Heat amount) Protein Casein Ca 50.0 g 200 kcal Lipid Soybean oil 105.0 g 945 kcal Carbohydrate dextrin 195.0 g 780 kcal Vitamins Vitamin A 1111 IU Vitamin B 1 778 μg Vitamin B 2 1000 μg Vitamin B 6 5.0mg vitamin B 12 4.4 [mu] g vitamin C 111 mg vitamin D 100 IU vitamin E 17.8 mg niacin 13.3mg folic 400μg pantothenate 7.8mg minerals sodium 150mg calcium 667mg potassium 300mg phosphate 200mg magnesium 100mg iron 11.1mg zinc 16.7mg Emulsifier Glycerin fatty acid ester 2g Dietary fiber Oligosaccharide 0.44g Flavor Milk flavor 0.90mL

【0043】蛋白質、脂質、糖質及び乳化剤を上記処方
の配合割合で混合し、その総量100重量部に対して水
150重量部を加え、70℃に昇温した。その際、グリ
セリン脂肪酸エステルはあらかじめ大豆油に溶解させた
後加え、この混合液を75℃で15分間予備乳化した
後、1段目150kg/cm2 、2段目50kg/cm
2 の2段均質法で均質化処理を行い乳化液を得、次いで
この乳化液を噴霧乾燥機で乾燥し、粉末油脂を得た。次
に、ビタミン、ミネラル、食物繊維および香料をホモミ
キサーにて混和し上記処方の配合割合を有する粉末組成
物を調製した。
The protein, lipid, saccharide and emulsifier are formulated as described above.
And mixed with water at 100 parts by weight of the total amount.
150 parts by weight were added, and the temperature was raised to 70 ° C. At that time,
Serine fatty acid ester was previously dissolved in soybean oil
The mixture was pre-emulsified at 75 ° C. for 15 minutes.
After the first stage 150kg / cmTwo50 kg / cm for the second stage
TwoTo obtain an emulsion by homogenizing treatment with the two-stage homogenization method
This emulsion was dried with a spray drier to obtain a powdered fat. Next
With vitamins, minerals, fiber and flavors
A powder composition mixed with a xer and having the above proportions
Was prepared.

【0044】実施例2 実施例1の処方に示す量のカゼインカルシウム、デキス
トリン、ミネラル分散液、レシチン、オリゴ糖、大豆油
を約65℃の純水に投入し混合した。各成分を混合後、
混合液をホモミキサーに投入し、約8000rpmで2
0分間粗乳化を行った。ついで、60℃に加温し10分
間静置した後、高圧乳化機にて精乳化(500kgf/
cm2 、2パス)を行った。得られた乳化液を約20℃
に冷却し、ビタミン類および香料を添加後、1Lにメス
アップを行った。充填タンクを約7℃に冷却し、200
rpmで攪拌しながら、得られた乳化液を投入した。つ
いで充填タンクからパウチへ本液225gを充填後、窒
素置換を行いながらパウチを密封し、121℃で14分
間殺菌を行った。殺菌したパウチには流動食500mL
が充填され、このものは100mL当たり200kca
lのエネルギーを有する。
Example 2 The amounts of calcium caseinate, dextrin, mineral dispersion, lecithin, oligosaccharides and soybean oil shown in the formulation of Example 1 were charged into pure water at about 65 ° C. and mixed. After mixing each component,
The mixed solution is charged into a homomixer, and is mixed at about 8000 rpm.
Coarse emulsification was performed for 0 minutes. Then, the mixture was heated to 60 ° C. and allowed to stand for 10 minutes, and then finely emulsified (500 kgf /
cm 2 , 2 passes). About 20 ° C
After adding vitamins and fragrance, the volume was increased to 1 L. Cool the filling tank to about 7 ° C,
The resulting emulsion was charged while stirring at rpm. Then, after filling 225 g of the present solution into the pouch from the filling tank, the pouch was sealed while purging with nitrogen, and sterilized at 121 ° C. for 14 minutes. 500mL liquid food for sterilized pouches
Is filled with 200 kca per 100 mL
1 energy.

【0045】[0045]

【発明の効果】以上のように、本発明の栄養組成物は、
従来の腎疾患患者用の栄養組成物に比べて、総熱量に占
める脂質の割合を増すことにより、腎臓への負担を増加
させることなく健常人と同等の蛋白質摂取が可能とな
り、栄養状態を改善できると共に、脂質代謝の改善によ
り動脈硬化やこれに起因する心血管系疾患を予防するこ
とができるという効果がある。
As described above, the nutritional composition of the present invention comprises:
By increasing the proportion of lipids in the total calories compared to conventional nutritional compositions for patients with renal disease, it is possible to obtain protein equivalent to that of healthy individuals without increasing the burden on the kidneys and improve nutritional status At the same time, there is an effect that arteriosclerosis and cardiovascular diseases resulting therefrom can be prevented by improving lipid metabolism.

【図面の簡単な説明】[Brief description of the drawings]

【図1】腎不全モデル動物の体重増加率を示すグラフで
ある。
FIG. 1 is a graph showing the rate of weight gain of a renal failure model animal.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61P 13/12 A61P 13/12 A61K 37/18 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI theme coat ゛ (Reference) A61P 13/12 A61P 13/12 A61K 37/18

Claims (2)

【特許請求の範囲】[Claims] 【請求項1】総熱量に占める脂質の割合が35〜70
%、蛋白質及び/又はその分解物の割合が8〜15%で
あり、且つ糖質の割合が57%以下である腎疾患患者用
栄養組成物。
(1) The proportion of lipids in the total heat is 35 to 70.
%, A ratio of a protein and / or a degradation product thereof is 8 to 15%, and a ratio of a carbohydrate is 57% or less.
【請求項2】総熱量に占める脂質の割合が35〜70
%、蛋白質及び/又はその分解物の割合が8〜15%で
あり、且つ糖質の割合が57%以下である腎不全患者用
栄養組成物。
2. The ratio of lipid to total calorie is 35 to 70.
%, A ratio of a protein and / or a degradation product thereof is 8 to 15%, and a ratio of a carbohydrate is 57% or less.
JP2000002493A 1999-01-11 2000-01-11 Nutritive composition for kidney disease patient Pending JP2000264844A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2000002493A JP2000264844A (en) 1999-01-11 2000-01-11 Nutritive composition for kidney disease patient

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP388499 1999-01-11
JP11-3884 1999-01-11
JP2000002493A JP2000264844A (en) 1999-01-11 2000-01-11 Nutritive composition for kidney disease patient

Publications (1)

Publication Number Publication Date
JP2000264844A true JP2000264844A (en) 2000-09-26

Family

ID=26337539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000002493A Pending JP2000264844A (en) 1999-01-11 2000-01-11 Nutritive composition for kidney disease patient

Country Status (1)

Country Link
JP (1) JP2000264844A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013514812A (en) * 2009-12-22 2013-05-02 ネステク ソシエテ アノニム Method for optimizing nutritional composition and dietary acid-base potential
JP2015187182A (en) * 2005-04-06 2015-10-29 ネステク ソシエテ アノニム Method and composition for nutritionally improving glucose control and insulin action
CN107106684A (en) * 2015-03-20 2017-08-29 株式会社明治 Renal function improver
US11077085B2 (en) * 2016-08-26 2021-08-03 Atif Dabdoub Dietary macro/micronutritional supplement for patients undergoing kidney dialysis
CN114271480A (en) * 2021-12-31 2022-04-05 烟台大学 High-stability end-stage nephropathy full-nutrition food emulsion and preparation process thereof
CN114630593A (en) * 2019-09-27 2022-06-14 国立大学法人大阪大学 Sugar-limited high-fat diet for improving chronic kidney disease

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015187182A (en) * 2005-04-06 2015-10-29 ネステク ソシエテ アノニム Method and composition for nutritionally improving glucose control and insulin action
JP2013514812A (en) * 2009-12-22 2013-05-02 ネステク ソシエテ アノニム Method for optimizing nutritional composition and dietary acid-base potential
CN107106684A (en) * 2015-03-20 2017-08-29 株式会社明治 Renal function improver
US11077085B2 (en) * 2016-08-26 2021-08-03 Atif Dabdoub Dietary macro/micronutritional supplement for patients undergoing kidney dialysis
US20210353578A1 (en) * 2016-08-26 2021-11-18 Atif Dabdoub Dietary macro/micronutritional supplement for patients undergoing kidney dialysis
CN114630593A (en) * 2019-09-27 2022-06-14 国立大学法人大阪大学 Sugar-limited high-fat diet for improving chronic kidney disease
CN114271480A (en) * 2021-12-31 2022-04-05 烟台大学 High-stability end-stage nephropathy full-nutrition food emulsion and preparation process thereof
CN114271480B (en) * 2021-12-31 2023-10-20 烟台大学 High-stability full-nutrition food emulsion for end stage renal disease and preparation process thereof

Similar Documents

Publication Publication Date Title
CN1104855C (en) Composition and its use as food supplement or for lowering lipids in serum
FI58579B (en) ANALYSIS OF HOUSE-AMYLOSSTAERKELSE VID FRAMSTAELLNING AV EN DIETFOEDOAEMNESKOMPOSITION
JP3545760B2 (en) Nutritional composition for controlling blood sugar level
CA1338427C (en) Nourishing products enriched with nucleosides and/or nucleotides for infants and adults and processes for their preparation
JP6346896B2 (en) Nutritional composition comprising calcium β-hydroxy-β-methylbutyrate, protein and low level electrolyte
US6156738A (en) Diabetic supplement bar
US5866555A (en) Diabetic supplement bar
US6221836B1 (en) Composition of pyruvate and anabolic protein and method for increasing fat loss in a mammal
AU3665701A (en) Carbohydrate system and a method for providing nutriton to diabetic
JP4116861B2 (en) Lowering blood cholesterol levels using cellulose ether
MX2011004314A (en) Liquid high-fat protein composition.
JPS6236645B2 (en)
US20160136124A1 (en) Administration of a food composition product
JP2012523840A (en) High fiber nutrition emulsion for blood glucose control
EP1065947A1 (en) Method for providing glutamine
CA2481705A1 (en) Hydrothermically processed compositions containing phytosterols
JP2000264844A (en) Nutritive composition for kidney disease patient
EP0537113A1 (en) Energy supplementary food
JP2012523841A (en) High fiber nutrition emulsion with glycerin
EP0388237A2 (en) Dietary product
JP2006022068A (en) Serum lipid metabolism ameliorative agent
JP2008247858A (en) Dietary composition for oral administration
US20230047152A1 (en) Hyperproteic snack-type food product with high biological value (hbv) for patients undergoing haemodialysis
US20020187179A1 (en) Non-steroidal anabolic compositions and associated methods
JP2001131065A (en) Body fat-reducing accelerator and food composition for body fat-reducing acceleration

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070612

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20071016